C0023884||Liver
C0015683||mono-unsaturated fatty acid synthase-1
C0014432||inhibitor
C0243095||anti-hepatitis C
C0087111||treatment
C0003451||antiviral agents
C4288963||hepatitis C virus (HCV) infection
C0042776||viruses
C0003451||anti-viral agents
C0033213||problem
C0013203||drug-resistant
C0042776||viruses
C1254351||drugs
C0220847||hepatitis C virus
C0003451||anti-viral agents
C1167179||replication complex
C0150312||present
C1948049||compartment
C0007634||cells
C0598783||lipid metabolism
C1254351||modulators
C0282629||virus assembly
C0220847||hepatitis C virus
C0042774||replication
C0038233||stearoyl-CoA desaturase
C0038233||stearoyl-CoA desaturase
C0014442||enzyme
C0015687||long-chain mono-unsaturated fatty acid
C0015687||long-chain mono-unsaturated fatty acid
C0220781||synthesis
C0220847||hepatitis C virus
C0042774||replication
C0038233||SCD-1
C0014432||inhibor
C0041755||side effects
C0015392||eyes
C1123023||skin
C0038233||SCD-1
C0014432||inhibitors
C4288963||hepatitis C virus
C0041755||side effects
C0038233||SCD-1
C0014432||inhibitors
C0023884||liver
C0038233||SCD-1
C0014432||inhibitor
C3252063||MK8245
C0243095||antidiabetic effects
C0241863||diabetic
C0025929||model mice
C1513916||no
C0041755||side effects
C0008972||clinical study
C3252063||MK8245
C3274448||tolerability
C1273937||no significant
C0041755||side effects
C4086204||ClinicalTrials.gov
C0023884||liver
C0038233||SCD-1
C0014432||inhibitors
C1254351||agents
C0220847||hepatitis C virus
C0439663||infected
C3252063||MK8245
C1516329||culture systems
C0220847||hepatitis C virus
C0087111||treatments
C0003451||anti-viral agents
C0042776||viruses
C0009429||combination therapy
C0003451||anti-viral agents
C1254351||agents
C3252063||MK8245
C0243095||anti-HCV effects
C0003451||anti-viral agents
C0854621||interferon-alpha therapy
C3252063||MK8245
C0243095||anti-HCV
C0013216||multi-drug therapy
C0013203||drug-resistant
C0220847||hepatitis C virus
C0041755||side effects